Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Insmed, Inc. (INSM)

Pharmaceutical Preparations

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

700 US HIGHWAY 202/206
BRIDGEWATER, NJ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/01/2000

Market Cap

13,143,011,520

Shares Outstanding

143,060,000

Weighted SO

143,062,065

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

ASND --.--%

APLS --.--%

BGNE --.--%

AKRO --.--%

BPMC --.--%

CERE --.--%

RNA --.--%

RVMD --.--%

DAWN --.--%

Beta

1.1610

Last Div

0.0000

Range

21.21-78.87

Chg

2.3400

Avg Vol

3590164

Mkt Cap

13143011520

Exch

NASDAQ

Country

US

Phone

908 977 9900

DCF Diff

3.6335

DCF

25.3235

Div Yield

0.0000

P/S

39.9964

EV Multiple

-20.9894

P/FV

304.7970

Div Yield %

0.0000

P/E

-14.7399

PEG

-0.6574

Payout

0.0000

Current Ratio

2.7057

Quick Ratio

2.5339

Cash Ratio

2.3787

DSO

44.7635

DIO

431.9937

Op Cycle

476.7572

DPO

246.3664

CCC

230.3908

Gross Margin

0.7684

Op Margin

-2.0345

Pretax Margin

-2.4337

Net Margin

-2.4427

Eff Tax Rate

-0.0037

ROA

-0.4434

ROE

3.0659

ROCE

-0.5199

NI/EBT

1.0037

EBT/EBIT

1.1962

EBIT/Rev

-2.0345

Debt Ratio

0.7415

D/E

34.5747

LT Debt/Cap

0.9661

Total Debt/Cap

0.9719

Int Coverage

-17.7744

CF/Debt

-0.4278

Equity Multi

46.6309

Rec Turnover

8.1540

Pay Turnover

1.4815

Inv Turnover

0.8449

FA Turnover

3.0199

Asset Turnover

0.1815

OCF/Share

-3.7113

FCF/Share

-3.8177

Cash/Share

8.0594

OCF/Sales

-1.7472

FCF/OCF

1.0287

CF Coverage

-0.4278

ST Coverage

-2.4233

CapEx Coverage

-34.8618

Div&CapEx Cov

-34.8618

P/BV

304.7970

P/B

304.7970

P/S

39.9964

P/E

-14.7399

P/FCF

-22.2534

P/OCF

-20.6076

P/CF

-20.6076

PEG

-0.6574

P/S

39.9964

EV Multiple

-20.9894

P/FV

304.7970

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 28, 15:57 Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report Benzinga Nov 20, 12:00 Where Insmed Stands With Analysts

Revenue Product Segmentation